Niagen Bioscience

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NAGE and other ETFs, options, and stocks.

About NAGE

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). 

CEO
Robert N. Fried
CEORobert N. Fried
Employees
117
Employees117
Headquarters
Los Angeles, California
HeadquartersLos Angeles, California
Founded
1999
Founded1999
Employees
117
Employees117

NAGE Key Statistics

Market cap
277.16M
Market cap277.16M
Price-Earnings ratio
15.53
Price-Earnings ratio15.53
Dividend yield
Dividend yield
Average volume
810.36K
Average volume810.36K
High today
$3.64
High today$3.64
Low today
$3.36
Low today$3.36
Open price
$3.49
Open price$3.49
Volume
1.11M
Volume1.11M
52 Week high
$11.90
52 Week high$11.90
52 Week low
$3.18
52 Week low$3.18

Stock Snapshot

As of today, Niagen Bioscience(NAGE) shares are valued at $3.49. The company's market cap stands at 277.16M, with a P/E ratio of 15.53.

During the trading session on 2026-07-13, Niagen Bioscience(NAGE) shares reached a daily high of $3.64 and a low of $3.36. At a current price of $3.49, the stock is +4.0% higher than the low and still -4.2% under the high.

Trading activity shows a volume of 1.11M, compared to an average daily volume of 810.36K.

The stock's 52-week range extends from a low of $3.18 to a high of $11.90.

The stock's 52-week range extends from a low of $3.18 to a high of $11.90.

NAGE News

Investing.com 10h
Niagen Bioscience receives FDA, EMA designations for rare disease drug - Investing.com

...

Niagen Bioscience receives FDA, EMA designations for rare disease drug - Investing.com
Simply Wall St 3d
Niagen Bioscience Stock Looks Reasonable On Earnings Yet Weak On Broader Checks

Niagen Bioscience stock has fallen sharply over the past year, yet over three years the share price is still ahead, leaving investors weighing a mixed valuation...

Niagen Bioscience Stock Looks Reasonable On Earnings Yet Weak On Broader Checks
TipRanks 5d
Niagen Bioscience launches pharmaceutical program for aging and genetic diseases

Niagen Bioscience (NAGE) formally launched the first drug candidate of NAD Pharmaceuticals, its wholly owned subsidiary focused on developing therapies for acce...

Analyst ratings

100%

of 6 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own NAGE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.